. Author manuscript; available in PMC: 2007 Aug 22.

Published in final edited form as: Int J Radiat Oncol Biol Phys. 2006 Jul 11;66(1):25–30. doi: 10.1016/j.ijrobp.2006.03.056

Table 5.

Multivariate analysis including bcl-2 results

Endpoint	Variable^#	Group	RR (95% CI)^*	p value^†
LF	Bcl-2	Positive	1.12 (0.57, 2.22)	0.74
	T-stage	T3	1.09 (0.53, 2.25)	0.81
	GLSC	7–10	1.39 (1.67, 2.91)	0.38
	STAD	Yes	0.63 (0.32, 1.22)	0.17
DM	Bcl-2	Positive	0.77 (0.42, 1.42)	0.40
	T-stage	T3	1.03 (0.58, 1.84)	0.93
	GLSC	7–10	2.50 (1.25, 5.02)	0.01
	STAD	Yes	0.53 (0.30, 0.92)	0.03
CSM	Bcl-2	Positive	0.87 (0.43, 1.78)	0.70
	T-stage	T3	0.98 (0.49, 1.95)	0.96
	GLSC	7–10	2.37 (1.04, 5.44)	0.04
	STAD	Yes	0.63 (0.33, 1.21)	0.17

Abbreviations: LF = local failure; DM = distant metastasis; CSM = cause specific mortality; GLSC = Gleason Score; STAD = short term androgen deprivation.

Relative Risk (RR): a risk ratio of 1 indicates no difference between the two subgroups. The 95% confidence intervals are shown in parentheses.

^†

p value from Chi-square test using the Cox proportional hazards model.

All variables were dichotomous.